Guggenheim raised the firm’s price target on Eli Lilly (LLY) to $1,183 from $1,163 and keeps a Buy rating on the shares. The firm is updating its model ahead of Q1 to reflect the disclosed IPR&D charge of $584M, representing 52c to EPS, and recently announced acquisitions of Centessa (CNTA) and Kelonia Therapeutics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Amazon (AMZN) Steps Up Weight Loss Push, Knocks HIMS Stock Off the Scale
- UBS Pounds the Table on Eli Lilly Stock (LLY) After Kelonia Therapeutics Deal
- Lilly, Novo slip after CVS opts out of Medicare obesity drug model
- Want a Monthly Dividend That Yields 20%? BlackRock (BLK) Has a Fund for You
- UnitedHealth sees ‘challenges’ with current Medicare weight loss drug plans